Health Care [ 11/12 ] | Biotechnology [ 55/73 ]
NASDAQ | Common Stock
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers.
Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018.
The company was incorporated in 2006 and is headquartered in Stafford, Texas.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 19, 25 | -0.25 Decreased by -31.58% | -0.24 Decreased by -4.17% |
| Feb 26, 25 | -0.61 Decreased by -185.31% | -0.21 Decreased by -190.48% |
| Nov 8, 24 | -0.20 Decreased by -7.41% | -0.21 Increased by +4.76% |
| Aug 21, 24 | -0.20 Decreased by -53.85% | -0.20 |
| May 20, 24 | -0.19 Decreased by -18.75% | -0.20 Increased by +5.00% |
| Mar 31, 24 | -0.21 Increased by +2.82% | -0.22 Increased by +2.82% |
| Oct 19, 23 | -0.19 Decreased by -3.44% | -0.22 Increased by +15.36% |
| Aug 21, 23 | -0.13 Decreased by -116.67% | -0.23 Increased by +43.48% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 3.61 K Decreased by -33.33% | -8.04 M Decreased by -225.09% | Decreased by -222.60 K% Decreased by -387.64% |
| Dec 31, 24 | 0.00 Decreased by N/A% | -8.04 M Decreased by -192.72% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -2.67 M Decreased by -11.58% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -2.61 M Decreased by -60.08% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 5.42 K Increased by +N/A% | -2.47 M Decreased by -23.12% | Decreased by -45.65 K% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -2.75 M Decreased by -4.06% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -2.39 M Decreased by -6.07% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -1.63 M Decreased by -126.53% | Decreased by N/A% Decreased by N/A% |